# Strategic Feedback — GPT-5.4 (R2)

**Role:** Journal editor (AER perspective)
**Model:** openai/gpt-5.4
**Timestamp:** 2026-03-11T21:19:26.245110
**Route:** OpenRouter + LaTeX
**Tokens:** 10886 in / 3847 out
**Response SHA256:** c97a1d3e7734eb4b

---

## 1. THE ELEVATOR PITCH

This paper asks whether statutory review deadlines at the FDA lead regulators to approve drugs on the margin in ways that later compromise patient safety. Using the sharp clustering of standard-review approvals at the 300-day PDUFA deadline, it shows that deadline bunching is real, but that the higher post-market adverse-event counts for deadline-approved drugs largely disappear once observable differences across drugs are accounted for.

Why should a busy economist care? Because this is, in principle, a clean and important version of a broad question: do bureaucratic performance targets distort the timing of decisions only, or the quality of those decisions too?

**Does the paper itself articulate this pitch clearly in the first two paragraphs?**  
Not quite. The introduction is stronger than average, but it spends too much time on institutional detail before crystallizing the big economic question. More importantly, it promises a sharper causal design than the paper ultimately wants to stand behind. The first paragraphs currently set up “deadline pressure causes lower-quality approvals?” but the paper’s actual core contribution is narrower: “the alarming raw correlation between deadline-window approval and worse post-market safety seems largely compositional.”

**What the first two paragraphs should say instead:**  
> Governments increasingly manage agencies through deadlines and performance clocks. These targets may speed decisions, but they may also distort quality if bureaucrats rush marginal cases to hit visible benchmarks. Drug regulation is an especially consequential setting for this tradeoff: the FDA faces statutory review deadlines under PDUFA, and a striking share of approvals occur exactly at the 300-day mark.
>
> This paper asks whether those deadline-induced approvals are less safe after launch. Using the bunching of standard-review drug approvals at the PDUFA deadline, I show that drugs approved at the deadline have worse raw post-market safety outcomes, but that these differences largely reflect which drugs bunch there and how long they have been on the market, not clear evidence that deadline pressure itself degrades review quality. The broader lesson is that bureaucratic deadlines can strongly distort the timing of action without obviously worsening measurable outcomes.

That is the pitch the paper should own.

---

## 2. CONTRIBUTION CLARITY

**Contribution in one sentence:**  
The paper documents strong deadline-induced bunching in FDA drug approvals and argues that the widely cited association between deadline-window approval and worse post-market safety is mostly due to drug composition and exposure differences rather than a clear causal safety penalty from review deadlines.

### Evaluation

**Is this contribution clearly differentiated from the closest 3–4 papers?**  
Only partially. The paper names some neighbors, but the differentiation is still muddy. The reader can tell it is related to the PDUFA speed-safety debate, but not sharply enough what this paper changes relative to:

- **Carpenter et al. / Carpenter’s broader work on FDA regulation and reputation**
- **Downing et al. (2017)** on approvals near deadlines and post-market safety problems
- **Berndt et al. / Olson-type work** on review speed and approval patterns
- The broader FDA review-time literature summarized by **Darrow et al.**

Right now the paper’s novelty is an awkward hybrid: “I use bunching/RD language” plus “I show the raw correlation goes away with controls.” That is not yet a crisp contribution. If the real advance over Downing is “they compare deadline-period drugs to others, but I show the apparent relationship is largely selection/composition,” then that has to be made brutally explicit.

**Is the contribution framed as answering a question about the world, or filling a gap in a literature?**  
It starts as a world question, which is good: do review deadlines lower regulatory quality? But it slips into literature-gap language (“first quasi-experimental estimate,” “apply bunching to regulation”) that is less compelling. The world question is the stronger frame. The methodology is not the reason an AER reader should care.

**Could a smart economist explain what’s new after reading the introduction?**  
Not confidently. They would probably say: “It’s a paper on FDA deadlines and safety; looks like another quasi-experimental/design-heavy paper on drug approvals.” The introduction does not cleanly separate:
1. the fact of bunching,
2. the debate over whether deadline approvals are riskier,
3. the paper’s actual conclusion that the scary correlation is mostly compositional.

That third point is the real novelty, and it gets buried.

**What would make the contribution bigger?**  
Specific ways to raise the ambition:

1. **Use outcome measures closer to true risk, not cumulative reports.**  
   Exposure-adjusted safety outcomes, event rates in a fixed post-launch window, prescriptions-adjusted adverse events, time-to-first-boxed-warning, or time-to-withdrawal would immediately make the substantive claim bigger and less vulnerable to “this is just reporting/exposure.”

2. **Make the paper about organizational distortion, not just drugs.**  
   The larger question is whether performance metrics distort public-sector quality. FDA is the setting, not the endpoint. This would pull the paper toward political economy/public economics/organizations, rather than leaving it as a niche pharma-regulation paper.

3. **Show the margin that actually moves.**  
   If the paper could characterize what kinds of drugs get pushed to the deadline—complexity, therapeutic novelty, sponsor type, review division—it would turn “bunching exists” into a more general claim about how bureaucracies triage under deadlines.

4. **Compare timing distortion versus quality distortion explicitly.**  
   The strongest version of the paper is: deadlines massively compress administrative timing but do not measurably worsen downstream safety. That contrast is potentially interesting. Right now it is implied, not emphasized.

---

## 3. LITERATURE POSITIONING

### Closest neighbors

The most relevant neighbors appear to be:

1. **Downing et al. (2017, JAMA/Internal Medicine orbit)** on approvals near PDUFA deadlines and post-market safety.
2. **Carpenter’s work** on FDA approval, reputation, and safety/speed tradeoffs, especially *Reputation and Power* and related papers.
3. **Darrow et al.** on FDA review times and regulatory performance.
4. **Berndt et al. / Olson-type papers** on review speed and pharmaceutical regulation.
5. On method and framing, indirectly, the **bunching literature**: **Saez (2010)**, **Kleven (2016)**. But these are not substantive neighbors; they are tools.

### How should the paper position itself?

It should primarily **build on and revise** the deadline-safety literature, especially Downing. Not attack in a combative way, but say plainly:

- Existing evidence shows a troubling correlation between approvals near deadlines and later safety problems.
- This paper revisits that claim using the deadline’s mechanical bunching.
- The main message is not “previous work was wrong” but “the alarming correlation appears to reflect selection/composition more than deadline-induced quality degradation.”

That is a clear and useful intervention.

### Is the paper currently too narrow or too broad?

It is oddly both.

- **Too narrow** as a drug-regulation paper if the main contribution is just one more empirical pass at PDUFA and FAERS.
- **Too broad** when it claims to contribute to “economics of regulation,” “optimal FDA review speed,” and “institutions shape health outcomes” all at once.

The right audience is not “everything in regulation and health.” It is the intersection of:
- regulation/public administration,
- health economics,
- political economy of bureaucratic incentives.

The paper should say: this is a case study of performance-target distortions in a high-stakes bureaucracy.

### What literature does the paper seem unaware of?

It needs stronger engagement with:

1. **Public administration / multitasking / performance targets**  
   Holmstrom-Milgrom-style multitasking, target-based governance, bureaucratic distortion under measurable performance metrics. This is the natural conceptual home of “deadlines change behavior.”

2. **Organizations / queuing / operations under targets**  
   There is a broad literature on service targets in hospitals, courts, schools, tax administration, and public agencies. The FDA clock could be presented as a particularly clean instance of target-driven bunching.

3. **State capacity / bureaucratic quality**  
   If the real result is that the FDA meets deadlines without obvious quality loss, that connects to the literature on bureaucratic competence, not only to FDA-specific debates.

### Is the paper having the right conversation?

Not quite. It is having too much of a conversation with econometric design papers and too little with the economics of targets and bureaucracy. The unexpected but more powerful framing is:

> PDUFA gives us a rare visible performance target in a high-stakes bureaucracy. The target powerfully distorts timing, but the evidence for distorted quality is much weaker.

That is a more interesting conversation than “I applied bunching to FDA approvals.”

---

## 4. NARRATIVE ARC

### Setup
The FDA operates under statutory review deadlines, and approvals cluster dramatically at those deadlines. This creates an intuitive fear: visible performance targets may lead bureaucrats to rush marginal decisions.

### Tension
Prior work and raw data suggest deadline-window approvals look less safe later. But that could reflect either true deadline-induced quality degradation or differences in what kinds of drugs happen to be approved there.

### Resolution
The paper finds the timing distortion is real and dramatic, but the apparent safety penalty largely disappears once compositional differences are considered.

### Implications
The broader implication is that bureaucratic deadlines can reshape the timing of action without necessarily reducing measurable quality, at least by the post-market safety outcomes studied here.

### Evaluation

There is **the outline of a good narrative arc**, but the paper does not execute it cleanly. The central narrative is fighting with the empirical architecture.

The current manuscript tells two competing stories:

1. **Story A:** “I have a quasi-experimental design using RD/bunching to estimate the causal effect of deadline pressure.”
2. **Story B:** “The RD is compromised/imprecise, so the paper’s preferred evidence is controlled OLS showing the raw correlation vanishes.”

Those two stories are not fully reconciled. As written, the paper spends a lot of rhetorical capital on an RD-style identification story that it later partially abandons. That creates a credibility and positioning problem even before one gets to technical details. It feels like a design in search of a publishable conclusion.

**What story should it be telling instead?**  
The clean story is:

- There is a remarkable institutional fact: approvals bunch at the deadline.
- This bunching has fueled a widespread belief that deadlines reduce safety.
- Re-examining the evidence, the paper shows that the timing distortion is clear but the quality distortion is much harder to find, and much of the raw relationship appears compositional.
- Therefore, deadline-based performance management may distort observable timing much more than underlying quality.

That is a coherent narrative. The current paper is close to it, but too distracted by trying to sound more causally definitive than the evidence supports.

---

## 5. THE “SO WHAT?” TEST

### What fact would I lead with at a dinner party of economists?

“About 12 percent of standard-review new drugs are approved in a single 10-day window right at the FDA’s 300-day PDUFA deadline—but once you account for what kinds of drugs these are and how long they’ve been on the market, they don’t look clearly less safe afterward.”

That is the best fact in the paper.

### Would people lean in or reach for their phones?

Some would lean in—especially health, public, and political economy economists—because the bunching fact is vivid and the broader issue of bureaucratic targets is important. But many would reach for their phones if the paper is pitched as “another FDA safety paper with noisy post-market outcomes.” The paper’s setting is interesting; its current framing makes it sound narrower than it has to be.

### What follow-up question would they ask?

Probably:  
**“If the outcomes are noisy and cumulative, how do we know this isn’t just differential exposure/reporting rather than true safety?”**

That is exactly the strategic issue. If the paper cannot answer that convincingly in framing terms, then the null result feels modest rather than belief-changing.

### If findings are null or modest, is the null interesting?

Potentially yes—but only if the paper makes the right case. The interesting null is not “we didn’t find significance.” The interesting null is:

> Even under intense and highly visible deadline pressure, a major regulator appears able to compress the timing of decisions without obvious deterioration in downstream safety.

That is a meaningful result about bureaucratic performance, not a failed attempt to find harm.

Right now the paper does not fully sell the null in that stronger way. It keeps apologizing for limited power, which is honest but strategically weak. It needs to convert the null from “absence of evidence” into “evidence that the distortion may be largely administrative rather than substantive,” while still acknowledging limits.

---

## 6. STRUCTURAL SUGGESTIONS

### What would make it read better?

1. **Shorten the methodological throat-clearing in the introduction.**  
   The introduction currently spends too much time advertising an RD/bunching design. Move some of that to later sections. Front-load the substantive result: there is dramatic bunching, but the scary safety correlation mostly disappears after accounting for composition.

2. **Reorganize the introduction around three claims.**
   - Fact 1: PDUFA creates massive deadline bunching.
   - Question: Does this harm quality?
   - Answer: Raw safety correlations are misleading; timing distortion is clearer than quality distortion.

3. **Demote some econometric detail to the appendix or empirical strategy section.**  
   The first-time reader does not need MSE-optimal bandwidth selection or local polynomial language in the introduction. That is not the selling point.

4. **Elevate the “timing vs quality distortion” result.**  
   This is the paper’s real conceptual takeaway and should appear earlier and more often.

5. **Shorten or remove generic contribution paragraphs.**  
   The paragraph claiming contributions to three literatures is boilerplate and overstates breadth. Replace it with a sharper positioning paragraph.

6. **The robustness and placebo sections should be leaner in the main text.**  
   Since this memo is not about adjudicating the design, my strategic advice is simple: keep only the robustness exercises that directly clarify the story. Everything else can go to the appendix.

7. **Conclusion currently mostly summarizes.**  
   It should instead do one thing: tell the reader what to believe about deadline-based governance after reading the paper.

### Is the paper front-loaded with the good stuff?

Moderately, but not enough. The vivid bunching fact is front-loaded; the most important substantive takeaway is not. The reader should not have to wait until the results section to learn that the headline result is “raw differences are scary; adjusted differences are small and imprecise.”

### Are results buried that should be in the main text?

The decomposition logic—time on market and therapeutic composition explain much of the raw gap—should be more central. That is the heart of the paper’s contribution.

---

## 7. WHAT WOULD MAKE THIS AN AER PAPER?

Bluntly: in current form, this is **not yet an AER paper**, mainly because the paper’s ambition and framing do not match the standard of “this changes how economists think about an important question.”

### What is the gap?

Mostly three things:

#### 1. Framing problem
The paper is stronger as a paper about **performance targets and bureaucratic quality** than as a paper about one FDA deadline and one safety dataset. It has not fully claimed that broader question.

#### 2. Scope problem
The outcomes are too narrow/noisy to support a top-journal conclusion of broad importance. To persuade top people in the field, the paper likely needs better downstream quality measures or a broader set of implications.

#### 3. Ambition problem
The manuscript is competent but safe. It documents bunching and then backs into a controlled-null result. For AER, the paper needs either:
- a bigger substantive punch,
- a broader conceptual frame,
- or stronger evidence on the quality margin.

### What would excite the top 10 people in this field?

A version of this paper that could say something like:

> “Statutory performance targets induce major bunching in high-stakes regulatory decisions, but across multiple measures of downstream quality the distortion appears concentrated in timing rather than substance.”

To make that credible, the author likely needs better quality outcomes and a more explicit connection to the economics of targets and bureaucratic multitasking.

### Single most impactful advice

**Reframe the paper away from “a quasi-experimental FDA safety study” and toward “what performance deadlines do to bureaucratic timing versus quality,” then align the evidence and introduction around that single contrast.**

That is the one change that would most improve its odds. If the author can’t change the data, they can still change the paper’s intellectual center of gravity. Right now the paper undersells the big idea and oversells the design.

---

### Strategic Assessment

- **Current framing quality:** Adequate
- **Contribution clarity:** Somewhat fuzzy
- **Literature positioning:** Could be stronger
- **Narrative arc:** Serviceable
- **AER distance:** Far
- **Single biggest improvement:** Reframe the paper as evidence on how bureaucratic performance deadlines distort timing much more clearly than quality, rather than as another narrow FDA safety design paper.